A British drug company aims to test a compound found in cannabis as a treatment for epilepsy, following a promising study using the chemical in rats and mice.
GW Pharmaceuticals said on Thursday that human clinical trials using cannabidivarin (CBDV) could start in 2013 after University of Reading scientists reported the previously little-studied chemical had potential as an anticonvulsant.